Rasilez HCT

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

aliskiren, għall-idroklorotijażide

Available from:

Noden Pharma DAC

ATC code:

C09XA52

INN (International Name):

aliskiren, hydrochlorothiazide

Therapeutic group:

Aġenti li jaġixxu fuq is-sistema renin-angiotensin

Therapeutic area:

Pressjoni għolja

Therapeutic indications:

Trattament ta 'pressjoni għolja essenzjali fl-adulti. Rasilez HCT huwa indikat f'pazjenti li l-pressjoni tad-demm ma tkunx ikkontrollata sew b'aliskiren jew hydrochlorothiazide użati waħidhom. Rasilez HCT huwa indikat bħala terapija ta 'sostituzzjoni f'pazjenti li jkunu kontrollati sew b'aliskiren u hydrochlorothiazide, mogħtija flimkien, bl-istess livell ta' doża tat - taħlita.

Product summary:

Revision: 17

Authorization status:

Irtirat

Authorization date:

2009-01-16

Patient Information leaflet

                                92
B. FULJETT TA’ TAGĦRIF
Prodott mediċinali li m’għadux awtorizzat
93
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
RASILEZ HCT 150 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
RASILEZ HCT 150 MG/25 MG PILLOLI MIKSIJIN B’RITA
RASILEZ HCT 300 MG/12.5 MG PILLOLI MIKSIJIN B’RITA
RASILEZ HCT 300 MG/25 MG PILLOLI MIKSIJIN B’RITA
Aliskiren/hydrochlorothiazide
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Rasilez HCT u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Rasilez HCT
3.
Kif għandek tieħu Rasilez HCT
4.
Effetti sekondarji possibbli
5.
Kif taħżen Rasilez HCT
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU RASILEZ HCT U GĦALXIEX JINTUŻA
X’INHU RASILEZ HCT
Din il-mediċina fiha żewġ sustanzi attivi, li jisimhom aliskiren u
hydrochlorothiazide. It-tnejn li huma
jgħinu sabiex tikkontrolla il-pressjoni għolja (ipertensjoni).
Aliskiren huwa inibitur ta’ renin. Huwa jnaqqas l-ammont ta’
angiotensin II li l-ġisem jista’
jipproduċi. B’angiotensin II il-vini tad-demm jidjiequ u
l-pressjoni tad-demm togħla. Bit-tnaqqis ta’
angiotensin II, il-vini tad-demm jistrieħu, u l-pressjoni tad-demm
titbaxxa.
Hydrochlorothiazide jagħmel parti minn grupp ta’ mediċini li
jissejħu dijuretiċi thiazide.
Hydrochlorothiazide iżid l-ammont ta’ awrina li tgħaddi, li ukoll
tbaxxi il-pressjoni tad-demm.
Dan jgħin biex ibaxxi l-pressjoni tad-demm għolja fil-pazjenti
adulti
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
Prodott mediċinali li m’għadux awtorizzat
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Rasilez HCT 150 mg/12.5 mg pilloli miksijin b’rita
Rasilez HCT 150 mg/25 mg pilloli miksija b’rita
Rasilez HCT 300 mg/12.5 mg pilloli miksija b’rita
Rasilez HCT 300 mg/25 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Rasilez HCT 150 mg/12.5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 150 mg aliskiren (bħala
hemifumarate) u 12.5 mg hydrochlorothiazide.
Eċċipjenti b’effett magħruf:
Kull pillola fiha 25 mg lactose (bħala monohydrate) u 24.5 mg wheat
starch.
Rasilez HCT 150 mg/25 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 150 mg aliskiren (bħala
hemifumarate) u 25 mg hydrochlorothiazide.
Eċċipjenti b’effett magħruf:
Kull pillola fiha 50 mg lactose (bħala monohydrate) u 49 mg lamtu
tal-qamħ.
Rasilez HCT 300 mg/12.5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 300 mg aliskiren (bħala
hemifumarate) u 12.5 mg hydrochlorothiazide.
Eċċipjenti b’effett magħruf:
Kull pillola fiha 25 mg lactose (bħala monohydrate) u 24.5 mg lamtu
tal-qamħ.
Rasilez HCT 300 mg/25 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 300 mg aliskiren (bħala
hemifumarate) u 25 mg hydrochlorothiazide.
Eċċipjenti b’effett magħruf
:
Kull pillola fiha 50 mg lactose (bħala monohydrate) u 49 mg lamtu
tal-qamħ.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita.
Rasilez HCT 150 mg/12.5 mg pilloli miksija b’rita
Pillola bajda, konvessa miż-żewġ naħat, b’għamla ovali miksija
b’rita stampata b’ “LCI” fuq naħa u
“NVR” fuq l-oħra.
Rasilez HCT 150 mg/25 mg pilloli miksija b’rita
Pillola ta’ lewn isfar ċar, konvessa miż-żewġ naħat,
b’għamla ovali miksija b’rita stampata b’“CLL”
fuq naħa u “NVR” fuq in-naħa l-oħra.
Rasilez HCT 300 mg/12.5 mg pilloli miksija b’rita
Pillola vjola fl-abjad, konvessa miż-
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-05-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-05-2022
Public Assessment Report Public Assessment Report Bulgarian 20-05-2022
Patient Information leaflet Patient Information leaflet Spanish 20-05-2022
Public Assessment Report Public Assessment Report Spanish 20-05-2022
Patient Information leaflet Patient Information leaflet Czech 20-05-2022
Public Assessment Report Public Assessment Report Czech 20-05-2022
Patient Information leaflet Patient Information leaflet Danish 20-05-2022
Public Assessment Report Public Assessment Report Danish 20-05-2022
Patient Information leaflet Patient Information leaflet German 20-05-2022
Public Assessment Report Public Assessment Report German 20-05-2022
Patient Information leaflet Patient Information leaflet Estonian 20-05-2022
Public Assessment Report Public Assessment Report Estonian 20-05-2022
Patient Information leaflet Patient Information leaflet Greek 20-05-2022
Public Assessment Report Public Assessment Report Greek 20-05-2022
Patient Information leaflet Patient Information leaflet English 20-05-2022
Public Assessment Report Public Assessment Report English 20-05-2022
Patient Information leaflet Patient Information leaflet French 20-05-2022
Public Assessment Report Public Assessment Report French 20-05-2022
Patient Information leaflet Patient Information leaflet Italian 20-05-2022
Public Assessment Report Public Assessment Report Italian 20-05-2022
Patient Information leaflet Patient Information leaflet Latvian 20-05-2022
Public Assessment Report Public Assessment Report Latvian 20-05-2022
Patient Information leaflet Patient Information leaflet Lithuanian 20-05-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-05-2022
Public Assessment Report Public Assessment Report Lithuanian 20-05-2022
Patient Information leaflet Patient Information leaflet Hungarian 20-05-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 20-05-2022
Public Assessment Report Public Assessment Report Hungarian 20-05-2022
Patient Information leaflet Patient Information leaflet Dutch 20-05-2022
Public Assessment Report Public Assessment Report Dutch 20-05-2022
Patient Information leaflet Patient Information leaflet Polish 20-05-2022
Public Assessment Report Public Assessment Report Polish 20-05-2022
Patient Information leaflet Patient Information leaflet Portuguese 20-05-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 20-05-2022
Public Assessment Report Public Assessment Report Portuguese 20-05-2022
Patient Information leaflet Patient Information leaflet Romanian 26-08-2020
Public Assessment Report Public Assessment Report Romanian 20-05-2022
Patient Information leaflet Patient Information leaflet Slovak 26-08-2020
Public Assessment Report Public Assessment Report Slovak 20-05-2022
Patient Information leaflet Patient Information leaflet Slovenian 26-08-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 26-08-2020
Public Assessment Report Public Assessment Report Slovenian 20-05-2022
Patient Information leaflet Patient Information leaflet Finnish 20-05-2022
Public Assessment Report Public Assessment Report Finnish 20-05-2022
Patient Information leaflet Patient Information leaflet Swedish 26-08-2020
Public Assessment Report Public Assessment Report Swedish 20-05-2022
Patient Information leaflet Patient Information leaflet Norwegian 20-05-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 20-05-2022
Patient Information leaflet Patient Information leaflet Icelandic 20-05-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 20-05-2022
Patient Information leaflet Patient Information leaflet Croatian 20-05-2022
Public Assessment Report Public Assessment Report Croatian 20-05-2022

View documents history